Azathioprine
- Generic Name
- Azathioprine
- Brand Names
- Azasan, Imuran, Jayempi
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7N7O2S
- CAS Number
- 446-86-6
- Unique Ingredient Identifier
- MRK240IY2L
- Background
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index. Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.
Azathiprine was granted FDA approval on 20 March 1968.
- Indication
Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.
- Associated Conditions
- Atopic Dermatitis, Crohn's Disease (CD), Immune Thrombocytopenia (ITP), Kidney Transplant Rejection, Lupus Nephritis, Multiple Sclerosis, Pericarditis, Psoriasis, Rheumatoid Arthritis, Uveitis
- Associated Therapies
- -
Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
- Conditions
- Inflammatory Bowel DiseaseUlcerative ColitisCrohn's Disease
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 3
- Registration Number
- NCT02413047
- Locations
- 🇺🇸
Indiana University Hospital, Indianapolis, Indiana, United States
Thiopurine Induced Pancreatitis in IBD Patients
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Shaare Zedek Medical Center
- Registration Number
- NCT02281799
- Locations
- 🇮🇱
Shaare Zedek, Jerusalem, Israel
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
- Conditions
- Crohn DiseaseRecurrenceAzathioprinePrevention
- Interventions
- Drug: AzathioprineDrug: Azathioprine in case of endoscopic recurrenceProcedure: IleocolonoscopyProcedure: Small bowel follow trough
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 63
- Registration Number
- NCT02247258
- Locations
- 🇨🇿
Univerzity Karlovy, Prague, Czech Republic
🇬🇷Evangelismos Hospital, Athens, Greece
🇧🇪Imelda Ziekenhuis, Bonheiden, Belgium
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Target Recruit Count
- 211
- Registration Number
- NCT02177071
- Locations
- 🇦🇺
St Vincent Hospital, Melbourne, Australia
🇫🇷Chu Clermont-Ferrand, Clermont-ferrand, Auvergne Rhone Alpes, France
🇫🇷CHU LYON, Pierre Benite, Auvergne Rhone Alpes, France
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 336
- Registration Number
- NCT02081755
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Northwestern University School of Medicine, Chicago, Illinois, United States
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01941095
- Locations
- 🇬🇷
Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens, Athens, Greece
🇬🇷Uni Hospital of Ioannina; Rheumatology, Ioannina, Greece
🇬🇷General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine, Thessaloniki, Greece
Infliximab Top-down in Pediatric Crohn
- Conditions
- Crohn's Disease
- Interventions
- First Posted Date
- 2013-06-18
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT01880307
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
🇮🇹Sapienza University, Rome, Italy
The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)
- Conditions
- Crohn's Disease
- Interventions
- Drug: azathioprine+enteral nutritionDrug: Azathioprine
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 100
- Registration Number
- NCT01823042
- Locations
- 🇨🇳
General Surgery Institute,Jinling Hospital, Nanjing, Jiangsu, China
Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Gastroenterology Research of America
- Target Recruit Count
- 65
- Registration Number
- NCT01817972
- Locations
- 🇺🇸
Gastroenterology Research of America, San Antonio, Texas, United States
The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 290
- Registration Number
- NCT01727193
- Locations
- 🇨🇳
The First Affiliated Hospital, SUN YAT-SEN UNIVERSITY, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.